CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
The Journal of pharmacology and experimental therapeutics Mar, 2015 | Pubmed ID: 25576073